August 2026 Issue

In this issue, we examine how linker chemistry has become a central lever for defining the therapeutic window. Explore why the whole ADC molecule has to be designed as one, and chart a bioconjugate landscape where developers are increasingly differentiating on construct rather than target.

"Parts of an ADC cannot be designed in isolation; the whole molecule has to be considered."
– Michael Lukesch, Founder and CEO, Valanx

"The linker cannot be optimized independently of the payload or the antibody, and it cannot be divorced from the target biology."
– Brian A Mendelsohn, Independent Industry Consultant and ADC Veteran